5 Cheapest Strong Buy Stocks to Buy Right Now

2. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

On March 30, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced that the U.S. Food and Drug Administration had approved Ponlimsi as a biosimilar to Prolia, with indications including the treatment of postmenopausal women with osteoporosis at high risk of fracture. The approval was supported by data demonstrating comparable efficacy, safety, and immunogenicity to the reference product, marking an important milestone in Teva’s biosimilars strategy and expanding its portfolio of complex generics and specialty products.

Earlier, on March 4, Piper Sandler raised its price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $41 from $40 while maintaining an Overweight rating following discussions with management. The firm highlighted growing confidence in Teva’s long-term growth trajectory, driven by its focus on innovative research and development, expansion in neuroscience and immunology, and continued progress in its biosimilars business. Additionally, improving cash generation and disciplined capital allocation are expected to support further balance sheet strengthening and potential valuation multiple expansion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a global leader in generic and specialty pharmaceuticals, headquartered in Tel Aviv, Israel, with a long-standing history dating back to 1901. The company operates across a wide range of therapeutic areas, leveraging its scale and expertise in both generics and innovative medicines. With increasing momentum in its biosimilars pipeline and improving financial fundamentals, Teva is well-positioned to deliver sustained growth, supporting a compelling investment case with meaningful upside potential.